CING vs AMTD Comparison

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

AMTD IDEA Group is a diversified institution and digital solutions conglomerate group, connecting companies and investors with world-wide markets. The group operates its businesses in five reportable and operating segments: capital market solutions segment, digital solutions and other services segment, media and entertainment segment, hotel operations, hospitality and VIP services segment, and strategic investment segment. The group generates the majority of its revenue from the strategic investment segment that engages in proprietary investments and management of world-wide investment portfolio (including listed and unlisted equity shares investments and movie rights investments). Its geographic areas are China, Europe, America, and Southeast Asia.